UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

The use of anti-TNF-alpha therapies for patients with systemic lupus erythematosus. Where are we now?

Lorenzo-Vizcaya, A; Isenberg, DA; (2021) The use of anti-TNF-alpha therapies for patients with systemic lupus erythematosus. Where are we now? Expert Opinion on Biological Therapy , 21 (5) pp. 639-647. 10.1080/14712598.2021.1853096. Green open access

[thumbnail of Isenberg_The use of anti-TNF-alpha therapies for patients with systemic lupus erythematosus. Where are we now_AAM.pdf]
Preview
Text
Isenberg_The use of anti-TNF-alpha therapies for patients with systemic lupus erythematosus. Where are we now_AAM.pdf - Accepted Version

Download (360kB) | Preview

Abstract

INTRODUCTION: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterized by multiple pathologies in which sustained inflammatory activity leads to progressive tissue destruction and organ damage. One of the main proinflammatory cytokines playing a key role in autoimmune diseases such as rheumatoid arthritis (RA) or SLE, is tumor necrosis factor (TNF) alpha. AREAS COVERED: The introduction of TNF-alpha inhibitors revolutionized the treatment of RA and other conditions including psoriatic arthritis and ankylosing spodylitis. We review here the efficacy and safety of TNF-alpha blockers in SLE focussing on why it has not been more widely used since TNF-alpha was reported to be increased in SLE patients and to correlate with disease activity. EXPERT OPINION: We summarize the reported SLE cases that have received TNF-alpha blockers and the main results to date. We reflect on whether there is a case to reconsider the use of TNF-alpha blockade in SLE.

Type: Article
Title: The use of anti-TNF-alpha therapies for patients with systemic lupus erythematosus. Where are we now?
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1080/14712598.2021.1853096
Publisher version: https://doi.org/10.1080/14712598.2021.1853096
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.
Keywords: SLE, TNF-alpha, biologics, infliximab, lupus nephritis, targets
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation
URI: https://discovery.ucl.ac.uk/id/eprint/10122035
Downloads since deposit
51Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item